Integration of host-related signatures with cancer cell-derived predictors for the optimal management of anticancer chemotherapy.
about
Merkel cell carcinoma in immunosuppressed patients.Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment.Improving lung cancer survival; time to move onBioinformatics tools for cancer metabolomics.Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer.Sequential metastases of colorectal cancer: Immunophenotypes and spatial distributions of infiltrating immune cells in relation to time and treatments.Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack.Hepatic metastases of colorectal cancer are rather homogeneous but differ from primary lesions in terms of immune cell infiltration.The role of the immune response in merkel cell carcinoma.How does ionizing irradiation contribute to the induction of anti-tumor immunity?Tumor-infiltrating lymphocyte therapy for melanoma: rationale and issues for further clinical development.The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment.High susceptibility of c-KIT+CD34+ precursors to prolonged doxorubicin exposure interferes with Langerhans cell differentiation in a human cell line model.Immune modulation by molecular cancer targets and targeted therapies: Rationale for novel combination strategiesMacrophage inflammatory protein-3 alpha (MIP-3a) is a novel serum prognostic marker in patients with colorectal cancer.
P2860
Q34309887-9D36E75F-B4D5-4B04-8DBD-F3013CE8B092Q34502899-3397F5AC-B9FF-4124-86C7-99E72C6B5896Q34509420-0F13CC5C-5E5A-4574-8A7E-4717035D90FAQ35163111-FD06C95B-A7FC-4BE4-B2B6-4FD03B506749Q36057423-15E4C65F-FA97-4A17-B82D-9DD8B544208EQ36194809-CB780B97-7B55-43E5-BC1D-2956FC33F15DQ36286833-AEE19FA1-FF4C-415D-833F-74008D98208CQ36845846-558409D3-C873-4E07-9E93-1D617FBECD0BQ37061729-2A0F1176-F757-4F69-B23B-392B90C54DE0Q38030920-1DFF8A7F-5F57-4448-B8CC-D6931DFE0EEDQ38217028-F150F8DB-E217-4CCE-A3EE-3AB62A249597Q38250205-472CC0BD-CF4E-436C-BACE-70F4E56F6367Q39571565-C9D979D3-5A72-488D-A88B-04BB2169D141Q41835981-E3E1D9CD-9FD3-4BC0-8D6B-1B11CD505B46Q43555198-32C64A02-80C1-49C9-9500-9C280BFBA8AC
P2860
Integration of host-related signatures with cancer cell-derived predictors for the optimal management of anticancer chemotherapy.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Integration of host-related si ...... nt of anticancer chemotherapy.
@en
Integration of host-related si ...... nt of anticancer chemotherapy.
@nl
type
label
Integration of host-related si ...... nt of anticancer chemotherapy.
@en
Integration of host-related si ...... nt of anticancer chemotherapy.
@nl
prefLabel
Integration of host-related si ...... nt of anticancer chemotherapy.
@en
Integration of host-related si ...... nt of anticancer chemotherapy.
@nl
P50
P1433
P1476
Integration of host-related si ...... nt of anticancer chemotherapy.
@en
P2093
Nicolas F Delahaye
P304
P356
10.1158/0008-5472.CAN-10-1003
P407
P577
2010-11-23T00:00:00Z